Inspire Medical Systems, Inc. Announces Preliminary Results for Second Quarter of 2024 and Updates 2024 Revenue Outlook
2024年7月29日 - 7:45PM
Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical
technology company focused on the development and commercialization
of innovative, minimally invasive solutions for patients with
obstructive sleep apnea, announced certain preliminary, unaudited
results for the quarter ended June 30, 2024, and updated full year
2024 revenue outlook. The company plans to report its complete
results and host its earnings conference call for the second
quarter of 2024 on August 6, 2024.
Preliminary, Unaudited Second Quarter
Revenue
- Revenue for the second quarter is anticipated to be $195.9
million, a 30% increase over the same quarter of 2023
- U.S. revenue is expected to be $187.8 million, a 30% increase
over the same quarter of 2023
- Revenue outside of the U.S. is expected to be $8.1 million, a
27% increase over the same quarter of 2023
Updated Full Year 2024 Revenue Guidance
- Revenue for full year 2024 is anticipated to be in the range of
$788 million to $798 million, which represents growth of 26% to 28%
over full year 2023. This represents a $13 million increase over
initial 2024 revenue guidance range of $775 million to $785
million.
“We are so proud of our team’s strong execution and revenue
performance in the second quarter, which showed sequential revenue
growth acceleration in the U.S.,” said Tim Herbert, Chairman and
CEO of Inspire. “With the strong momentum we are seeing in our
business, we have increased confidence regarding strong continued
revenue growth in the second half of 2024. As a result, we are
increasing our revenue guidance to $788 million to $798 million for
full year 2024. We look forward to reporting full results on August
6th,” concluded Tim Herbert.
About Inspire Medical SystemsInspire is a
medical technology company focused on the development and
commercialization of innovative, minimally invasive solutions for
patients with obstructive sleep apnea. Inspire’s proprietary
Inspire therapy is the first and only FDA, EU MDR and PDMA-approved
neurostimulation technology of its kind that provides a safe and
effective treatment for moderate to severe obstructive sleep
apnea.
For additional information about Inspire, please visit
www.inspiresleep.com.
Forward Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements
other than statements of historical facts are forward-looking
statements, including, without limitation, statements regarding our
preliminary, unaudited second quarter revenue results, and our
expectations regarding full year 2024 revenue outlook.
In some cases, you can identify forward-looking statements by terms
such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’
‘‘anticipate,’’ ‘‘could,’’ “future,” “outlook,” “guidance,”
‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’
‘‘estimate,’’ ‘‘predict,’’ ‘‘potential,’’ ‘‘continue,’’ or the
negative of these terms or other similar expressions, although not
all forward-looking statements contain these words.
These forward-looking statements are based on management’s
current expectations and involve known and unknown risks and
uncertainties that may cause our actual results, performance, or
achievements to be materially different from any future results,
performance, or achievements expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others, estimates regarding the annual total addressable
market for our Inspire therapy in the U.S. and our market
opportunity outside the U.S.; future results of operations,
financial position, research and development costs, capital
requirements and our needs for additional financing; commercial
success and market acceptance of our Inspire therapy; the impact of
macroeconomic trends; general and international economic,
political, and other risks, including currency, inflation, stock
market fluctuations and the uncertain economic environment; our
ability to achieve and maintain adequate levels of coverage or
reimbursement for our Inspire system or any future products we may
seek to commercialize; competitive companies and technologies in
our industry; our ability to enhance our Inspire system, expand our
indications and develop and commercialize additional products; our
business model and strategic plans for our products, technologies
and business, including our implementation thereof; our ability to
accurately forecast customer demand for our Inspire system and
manage our inventory; our dependence on third-party suppliers,
contract manufacturers and shipping carriers; consolidation in the
healthcare industry; our ability to expand, manage and maintain our
direct sales and marketing organization, and to market and sell our
Inspire system in markets outside of the U.S.; risks associated
with international operations; our ability to manage our growth;
our ability to increase the number of active medical centers
implanting Inspire therapy; our ability to hire and retain our
senior management and other highly qualified personnel; risk of
product liability claims; risks related to information technology
and cybersecurity; risk of damage to or interruptions at our
facilities; our ability to commercialize or obtain regulatory
approvals for our Inspire therapy and system, including our next
generation Inspire therapy system, or the effect of delays in
commercializing or obtaining regulatory approvals; FDA or other
U.S. or foreign regulatory actions affecting us or the healthcare
industry generally, including healthcare reform measures in the
U.S. and international markets; and the timing or likelihood of
regulatory filings and approvals. Other important factors that
could cause actual results, performance or achievements to differ
materially from those contemplated in this press release can be
found under the captions “Risk Factors” and "Management's
Discussion and Analysis of Financial Condition and Results of
Operations“ in our Annual Report on Form 10-K for the fiscal year
ended December 31, 2023, as updated in our Quarterly Report on Form
10-Q for the quarter ended March 31, 2024 to be filed with the SEC,
and as such factors may be updated from time to time in our other
filings with the SEC, which are accessible on the SEC’s website at
www.sec.gov and the Investors page of our website at
www.inspiresleep.com. These and other important factors could cause
actual results to differ materially from those indicated by the
forward-looking statements made in this press release. Any such
forward-looking statements represent management’s estimates as of
the date of this press release. While we may elect to update such
forward-looking statements at some point in the future, unless
required by applicable law, we disclaim any obligation to do so,
even if subsequent events cause our views to change. Thus, one
should not assume that our silence over time means that actual
events are bearing out as expressed or implied in such
forward-looking statements. These forward-looking statements should
not be relied upon as representing our views as of any date after
the date of this press release.
Investor and Media ContactEzgi YagciVice
President, Investor
Relationsezgiyagci@inspiresleep.com617-549-2443
Inspire Medical Systems (NYSE:INSP)
過去 株価チャート
から 6 2024 まで 7 2024
Inspire Medical Systems (NYSE:INSP)
過去 株価チャート
から 7 2023 まで 7 2024